Neuren appoints Chief Operating Officer

Neuren appoints Chief Operating Officer

18 July 2006: Neuren Pharmaceuticals (ASX: NEU) announced today the appointment of Dr Parmjot Bains to the position of Chief Operating Officer.

Dr Bains will be responsible for the operation of the clinical trial programs, ensuring overall responsibility for the budgets and milestones and also that all manufacturing, monitoring and reporting objectives are met. Currently Neuren has two clinical trials on track, with this planned to go to four during the 2007 year. Dr Bains will provide the overall coordination and management of this programme with the CMO, Dr Doug Wilson providing strategic input and the FDA regulatory interface.

Dr Bains’ previous role was leading a US$100 million division of Fonterra Co-operative Group Limited that researches, develops, markets and sells specialty and other products globally. Her previous positions included Biotech Business Development Manager responsible for new product development and IP/regulatory affairs.

Prior to that she worked at McKinsey and Company for four years based in Sydney. Dr Bains has also spent time with venture capital firm, Rubicon, and the World Health Organisation.

Dr Bains has completed a Masters of Philosophy at Cambridge University (UK) under a Commonwealth Scholarship and a Bachelor of Medicine and Surgery at Auckland University (NZ) where she was the highest ranked final year graduate, going on to work as a clinician at Sydney Children’s Hospital.

Mr David Clarke, Chief Executive Officer of Neuren commented: “On behalf of the Board we would like to welcome Parmjot to her position. Her exceptional experience in a broad range of management, science, medicine and finance will complement the variety of activities she will be overseeing.”

About Neuren Pharmaceuticals
Neuren Pharmaceuticals (ASX: NEU) is a biotechnology company developing novel therapeutics in the fields of neurotherapy and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has two lead candidates, Glypromate® and NNZ-2566, targeting a range of acute and chronic neurological conditions. Neuren has commercial and development partnerships, including Pfizer, the US Army’s Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren’s website at www.neurenpharma.com

ENDS

© Scoop Media